Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 413, 35-45
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81672952, 81430060)
- Guangdong Science and Technology Program (2014A030313196, 2013B051000034)
- Guangzhou Technology Program (201504010038, 201508020250, LCY201317)
This publication has 41 references indexed in Scilit:
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasJournal of Medicinal Chemistry, 2016
- Epigenome-Based Personalized Medicine in human CancerEpigenomics, 2015
- Design, Synthesis, and Structure–Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine–Thiourea Hybrids As Potent, Orally Active Antitumor AgentsJournal of Medicinal Chemistry, 2015
- EZH2 in normal and malignant hematopoiesisLeukemia, 2013
- Interplay between the Cancer Genome and EpigenomeCell, 2013
- Therapy‐related myeloid neoplasms: pathobiology and clinical characteristicsBritish Journal of Pharmacology, 2011
- Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancersInternational Journal of Cancer, 2010
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- Chromatin Compaction by a Polycomb Group Protein ComplexScience, 2004
- Histone Methyltransferases Direct Different Degrees of Methylation to Define Distinct Chromatin DomainsMolecular Cell, 2003